Skip to main content

Drug Interactions between dolutegravir / lamivudine and orlistat

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

lamiVUDine orlistat

Applies to: dolutegravir / lamivudine and orlistat

MONITOR: Orlistat may theoretically reduce the gastrointestinal absorption and therapeutic efficacy of antiretroviral agents. The mechanism may involve retention of lipophilic medicines in the gastrointestinal tract or reduced gastrointestinal tract transit time. Data have been reported for efavirenz and lopinavir. Other antiretroviral agents may also be affected.

MANAGEMENT: The potential reduction in antiretroviral efficacy should be considered before initiating treatment with orlistat. Patients who take antiretroviral medications should be advised to consult their physician before using the non-prescription brand of orlistat.

References

  1. MHRA. Medicines and Healthcare Products Regulatory Agency (2014) Orlistat: theoretical interaction with antiretroviral HIV medicines. http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON392868

Switch to consumer interaction data

Moderate

orlistat dolutegravir

Applies to: orlistat and dolutegravir / lamivudine

MONITOR: Orlistat may theoretically reduce the gastrointestinal absorption and therapeutic efficacy of antiretroviral agents. The mechanism may involve retention of lipophilic medicines in the gastrointestinal tract or reduced gastrointestinal tract transit time. Data have been reported for efavirenz and lopinavir. Other antiretroviral agents may also be affected.

MANAGEMENT: The potential reduction in antiretroviral efficacy should be considered before initiating treatment with orlistat. Patients who take antiretroviral medications should be advised to consult their physician before using the non-prescription brand of orlistat.

References

  1. MHRA. Medicines and Healthcare Products Regulatory Agency (2014) Orlistat: theoretical interaction with antiretroviral HIV medicines. http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON392868

Switch to consumer interaction data

Drug and food interactions

Minor

dolutegravir food

Applies to: dolutegravir / lamivudine

Food increases the extent of absorption and slows the rate of absorption of dolutegravir. When administered with a low-, moderate- or high-fat meal, dolutegravir peak plasma concentration (Cmax) increased by 46%, 52% and 67%, systemic exposure (AUC) increased by 33%, 41% and 66%, and time to reach Cmax (Tmax) increased from 2 hours to 3, 4 and 5 hours, respectively, compared to administration under fasted conditions. Dolutegravir may be taken with or without food.

References

  1. (2013) "Product Information. Tivicay (dolutegravir)." ViiV Healthcare

Switch to consumer interaction data

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer